Led · Series B · Jul 2026

Epitel develops the REMI Remote EEG Monitoring System, a wireless, wearable EEG platform designed to enable extended-duration brain monitoring at home for days to weeks. The REMI portfolio has received five U.S. FDA 510(k) clearances across its wireless EEG monitoring and AI-driven event detection technologies. REMI Vigilenz AI analyzes REMI EEG to flag potential seizures and is cleared for use in patients aged six and older, while the overall platform is cleared for patients as young as one year. Epitel is initially focused on seizure detection and diagnosis and cites gaps in access—noting 9.2 million Americans experience seizures annually while many lack EEG access. The company says its technology aims to improve clinician workflow by accelerating capture of objective seizure evidence and to broaden access to neurological care outside traditional hospital settings. With the recently closed Series B, Epitel plans to expand its commercial infrastructure and field team to accelerate adoption and market penetration.

Participated · Series C · Mar 2026

Tropic Biosciences develops gene-edited tropical crops via its proprietary GEiGS® platform, concentrating on banana and rice varieties designed for higher yields, increased disease resistance, and improved sustainability. In 2025 the company launched the first new banana varieties in more than 75 years, including a non-browning banana named one of TIME Magazine’s Best Inventions of 2025 and an extended shelf-life variety that increases green life by 12 days and can reduce waste by up to 50 percent. Tropic has made progress toward resistance to Panama Disease TR4 and shipped plants in 2025 to establish a mother plantation intended to support commercial deployment beginning in 2027. Demand for its new banana varieties has already surpassed supply, and the company has cited significant revenue growth as it scales. Tropic plans to expand its research across its rice portfolio and pursue additional high-impact, climate-resilient crops to address global food security and sustainability challenges.

Led · Seed · Nov 2025

Hermes Biosciences is a life-science tools startup focused on turning extracellular vesicles (EVs) into a practical and standardized resource for precision medicine. Its flagship product is a benchtop, fully automated instrument designed to isolate EVs at higher yield and purity than existing approaches, enabling more reliable downstream analysis for clinical researchers in academia, biopharma, and diagnostic laboratories. The company intends to launch its first commercial instrument in 2026, offering a scalable and hands-off workflow that can be integrated into regulated clinical environments. By improving EV capture, Hermes aims to advance biomarker discovery, non-invasive diagnostics, and targeted therapeutics. The San Francisco-based team is still pre-revenue, using newly secured capital to complete product development, expand manufacturing capabilities, and build out sales channels. The firm’s initial $6 million seed financing may grow as additional investors are engaged, giving Hermes runway to reach its commercialization milestones.

Participated · Series B · Jul 2025

Aqtual’s core product is a proprietary active chromatin cfDNA platform that integrates DNA, epigenetic regulation, and protein–DNA binding into a single blood-based assay to quantify tissue-specific gene regulation. The platform profiles disease biology, microenvironment, and systemic immune response from cell-free DNA fragments to enable real-time analysis of disease and treatment. Aqtual is advancing a flagship therapy-response prediction test in rheumatoid arthritis and is actively enrolling patients in the PRIMA-102 prospective observational clinical trial (more than 1,300 patients enrolled; expected completion Q4 2025). The company plans to present new data and its commercialization plans at major rheumatology and diagnostics meetings in the second half of 2025. Financially, Aqtual recently completed an oversubscribed $31 million Series B, with participation from new and previous investors and additional capital from a strategic diagnostics partner. The funding is positioned to advance the internal pipeline and support near-term commercialization efforts. Aqtual develops a proprietary cell-free DNA platform that analyzes previously unexplored circulating DNA fragments to evaluate protein regulation, epigenetics, and transcriptomics. The platform catalogs regulatory features at high resolution, including roughly 200,000 gene promoters, 400,000 enhancers, 50,000 insulators, 20,000 silencers, and 1 million transcription factor binding sites. Aqtual says this approach provides an order-of-magnitude greater detail into gene regulation than other cell-free DNA methods and can support diagnostics and drug-discovery applications. The company has initiated PRIMA-102, a prospective multi-center clinical trial (NCT05936970) in rheumatoid arthritis and has enrolled the first patient; the study plans to enroll 150 individuals to develop a classifier that predicts effective drug classes. Aqtual plans to use the assay to help physicians select the best treatments for rheumatoid arthritis patients and to expand applications across major disease areas. The company highlights potential for improved treatment decisions, faster selection of effective therapies, and new roadmaps for drug development.

Led · Series A · Jun 2024

Alida Biosciences, led by CEO Dr. Gudrun Stengel, develops epigenomic and epitranscriptomic research tools. Its core offerings include the EpiPlex RNA Library Prep Kit and the EpiScout Analysis Suite, which provide an integrated wet‑lab and bioinformatics solution for multiplexed detection and analysis of RNA modifications. The EpiPlex kit is positioned for profiling multiple RNA modifications in input‑limited clinical research samples, offering sensitivity and relative quantification on clinically relevant RNA inputs. EpiScout complements the kit by providing an intuitive platform to analyze and visualize complex epitranscriptomic data and support multiomic integration. The company says its products broaden the application of epitranscriptomics by enabling concurrent analysis of multiple RNA modifications with user‑friendly data interpretation. Alida raised $7.5M in a Series A and intends to use the proceeds to further enhance product development and bring the EpiPlex kit to market.